Neoleukin Therapeutics is a biopharmaceutical company, focused on immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. Co. is focused on key cytokine mimetics, which Co. refers to as Neoleukin de novo cytokine mimetics, that can be modified to adjust affinity, thermodynamic stability, resistance to biochemical modification, pharmacokinetic characteristics, potency and targeting to tumor or inflamed tissues. Co.'s NL-201 is designed to mimic the therapeutic activity of the cytokines interleukin-2 and interleukin-15 for the potential treatment of various types of cancer, including renal cell carcinoma, melanoma, and hematological malignancies. We show 19 historical shares outstanding datapoints in our coverage of NLTX's shares outstanding history.
Understanding the changing numbers of NLTX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like NLTX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching NLTX by allowing them to research NLTX shares outstanding history
as well as any other stock in our coverage universe. |
Free NLTX Email Alerts:
Video: Shares Outstanding Importance
